Abstract:HIV envelope transmembrane glycoproteins gp41 (HIV-1) and gp36 (HIV-2) present high variability and play a key role in the HIV-host cell membrane's fusion, as a target for human broadly neutralizing antibodies (bnAbs) and drugs. Thus, a better knowledge of amino acid (aa) conservation across structural domains and HIV variants can help to identify conserved targets to direct new therapeutic and diagnostic strategies. All available gp41/gp36 nucleotide sequences were downloaded from Los Alamos National Laboratory (LANL) HIV Sequence Database, selecting 17,078 sequences ascribed to HIV-1 and HIV-2 variants with ≥3 sequences. After aligning and translating into aa with MEGAv6.0, an in-house bioinformatics program (EpiMolBio) was used to identify the most conserved aa and the aa changes that were specific for each variant (V-markers) vs. HXB2/BEN (HIV-1/HIV-2) reference sequence. We analyzed the presence of specific aa changes among V-markers affecting infectivity, gp41 structure, function, or resistance to the enfuvirtide viral fusion inhibitor (T-20). We also inferred the consensus sequences per HIV variant, describing in each HIV-1 group (M, N, O, P) the conservation level along the complete gp41 per structural domain and locating in each binding site the anti-gp41 human Abs (bnAbs and non bnAbs) described in LANL. We found 38.3/59.7% highly conserved aa present in ≥90% of the 16,803/275 gp41/gp36 sequences ascribed to 105/3 HIV-1/HIV-2 variants, with 9/12.6% of them showing complete conservation across LANL sequences. The fusion peptide, its proximal region, the N-heptad repeat, and the membrane-proximal external region were the gp41 domains with ≥84% of conserved aa in the HIV-1 consensus sequence, the target of most Abs. No natural major resistance mutations to T-20 were observed. Our results show, for the first time, a complete conservation study of gp41/gp36 per variant in the largest panel of HIV variants analyzed to date, providing useful information for a more rational design of drugs, vaccines, and molecular detection tests targeting the HIV transmembrane glycoprotein.

A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design.

A Conserved Structural Motif Shared by EIAV Gp90 and HIV Gp120

Neutralizing Epitopes in the Membrane-Proximal Region of Hiv-1 Gp41: Genetic Variability and Co-Variation

Levels of N-linked Glycosylation on the V1 Loop of HIV-1 Env Proteins and Their Relationship to the Antigenicity of Env from Primary Viral Isolates.

N- and C-domains of HIV-1 gp41: mutation, structure and functions.

HIV Transmembrane Glycoprotein Conserved Domains and Genetic Markers Across HIV-1 and HIV-2 Variants

The antigenic tip GPGRAFY of the V3 loop on HIV-1 gp120: genetic variability and subtypes.

Enhancement of Human Immunodeficiency Virus Type 1 Infection by Antisera to Peptides from the Envelope Glycoproteins Gp120/gp41.

The Glycan‐mediated Mechanism on the Interactions of Gp120 with CD4 and Antibody: Insights from Molecular Dynamics Simulation

Single N277A Substitution in C2 of Simian Immunodeficiency Virus Envelope Influences Vaccine-Elicited CD4i Neutralizing and Anti-V2 Antibody Responses.

Sequence variation and consensus sequence of V3 loop on HIV-1 gp120.

Structural Characteristics and Biological Functions of the HIV-1 Gp120 V3 Region

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.

Epitope-Vaccines: A New Strategy to Induce High Levels of Neutralizing Antibodies Against Hiv-1

Altering the Specificity of the Antibody Response to HIV Gp120 with a Glycoconjugate Antigen.

HIV-1 Gp41 and Type I Interferon: Sequence Homology and Biological As Well As Clinical Implications.

Three Candidate Peptide-Vaccines in Combination to Induce High Levels of Multiantibodies Against HIV-1

Hiv-1 Gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad Hiv-1 Neutralizing Antibodies

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

The Neutralizing Epitope ELDKWA on HIV-1 Gp41: Genetic Variability and Antigenicity